Dexamethasone sodium phosphate Ophthalmic Solution Rx
Generic Name and Formulations:
Dexamethasone sodium phosphate 0.1%; oph soln; contains benzalkonium chloride.
Indications for Dexamethasone sodium phosphate Ophthalmic Solution:
Steroid responsive inflammatory conditions of the eye.
Initial therapy: 1 or 2 drops in conjunctival sac every hour during the day and every two hours during the night. When favorable response observed, reduce dose to 1 drop every 4 hours; may reduce later to 1 drop 3 or 4 times daily.
Epithelial herpes simplex keratitis. Acute infectious stages of vaccinia, varicella, and many other diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular or auricular structures. Perforation of a drum membrane.
Monitor intraocular pressure if used for >10 days. Wait at least 15 minutes before inserting contact lenses. Pregnancy (Cat.C). Nursing mothers: not recommended.
Glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, perforation of the globe; rare: stinging, burning, filtering blebs following cataract surgery.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline